Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis
Description
Purpose: To establish the theoretical framework and study the feasibility of 211At-labeled anti-tenascin chimeric 81C6 monoclonal antibody (mAb) as anti-vascular endoradiotherapy for the treatment of glioblastoma multiforme (GBM) tumors. Methods and Materials: The morphology of blood vessels from histologic images was analyzed and used along with reaction-diffusion equations to assess the activity concentration of 211At-labeled chimeric 81C6 mAb in GBM tumor and normal-brain tissue. Alpha particle microdosimetry was then used to assess the survival probability and average absorbed dose for tumor and normal tissue endothelial cells (ECs) per unit vascular cumulated activity concentration qsource (MBq-s g-1). In turn, these survival probabilities were used to assess the probability of failure PHI for a single vessel. Furthermore, using the vessel density, the specific tumor control probability per unit mass of tumor tissue (tcp) and the specific normal-tissue complication probability per unit mass of normal-brain tissue (ntcp) were estimated. The specific tumor control probability, tcp, was used to assess the overall tumor control probability (TCP) as a function of tumor mass. Results: The levels of 211At-labeled ch81C6 mAb cumulated activity concentration in GBM tumor tissue were approximately five times higher than that in normal-brain tissue. Thus, the average absorbed dose to tumor ECs was higher than that of normal tissue ECs, and the survival probability for GBM ECs was lower than for normal-brain tissue ECs. Consequently, the resulting vessel-failure probability, PHI, for GBM tumor and for normal-brain tissue differ considerably, yielding a qsource range between 103 and 104 MBq-s g-1. Conclusions: This theoretical analysis demonstrated that 211At-labeled chimeric 81C6 is an effective anti-vascular therapy for the treatment of GBM tumors, yielding a tcp higher than 0.999 for vascular cumulated activity concentrations qsource higher than 1 x 104 MBq-s g-1, while yielding a low probability for normal-brain tissue damage
Additional details
Identifiers
- PII
- S036030160203794X;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 54
- Journal Issue
- 4
- Journal Page Range
- p. 1259-1275
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 34012633
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ALPHA PARTICLES; ASTATINE 211; BRAIN; GLIOMAS; MICRODOSIMETRY; MONOCLONAL ANTIBODIES; RADIATION CHIMERAS; RADIATION DOSES; RADIOIMMUNOTHERAPY
- Descriptors DEC
- ALPHA DECAY RADIOISOTOPES; ANTIBODIES; ASTATINE ISOTOPES; BETA DECAY RADIOISOTOPES; BODY; CENTRAL NERVOUS SYSTEM; CHARGED PARTICLES; CHIMERAS; DISEASES; DOSES; DOSIMETRY; ELECTRON CAPTURE RADIOISOTOPES; HEAVY NUCLEI; HOURS LIVING RADIOISOTOPES; IMMUNOTHERAPY; IONIZING RADIATIONS; ISOTOPES; MEDICINE; MOSAICISM; NEOPLASMS; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NUCLEAR MEDICINE; NUCLEI; ODD-EVEN NUCLEI; ORGANS; RADIATIONS; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2002 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.